Atlas Trials

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Clinical trial NCT03278626 · TERMINATED

Trial details

NCT number
NCT03278626
Sponsor
NYU Langone Health
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2017-06-27
Primary completion
2019-11-07
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.